Stéphane Bancel, Moderna CEO (Steven Ferdman/Getty Images)
December 10, 2020 07:01 AM ESTUpdated 09:31 AM
Coronavirus

Covid-19 roundup: Mod­er­na be­gins PhII/III vac­cine study in ado­les­cents; Pfiz­er and BioN­Tech's vac­cine gets an OK in Cana­da as the FDA meets to dis­cuss emer­gency use

Nicole DeFeudis

Editor

Mod­er­na has launched a Phase II/III study of its Covid-19 vac­cine in ado­les­cents younger than 18 and old­er than 12, with the goal of read­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

A service from the Financial Times